Production and regulatory issues for theranostics Review
| Authors: | Giammarile, F.; Paez, D.; Zimmermann, R.; Cutler, C. S.; Jalilian, A.; Korde, A.; Knoll, P.; Ayati, N.; Lewis, J. S.; Lapi, S. E.; Delgado Bolton, R. C.; Kunikowska, J.; Estrada Lobato, E.; Urbain, J. L.; Holmberg, O.; Abdel-Wahab, M.; Scott, A. M. |
| Review Title: | Production and regulatory issues for theranostics |
| Abstract: | Theranostics has become a major area of innovation and progress in cancer care over the last decade. In view of the introduction of approved therapeutics in neuroendocrine tumours and prostate cancer in the last 10 years, the ability to provide access to these treatments has emerged as a key factor in ensuring global benefits from this cancer therapy approach. In this Series paper we explore the issues that affect access to and availability of theranostic radiopharmaceuticals, including supply and regulatory issues that might affect the availability of theranostic treatments for patients with cancer. © 2024 Elsevier Ltd |
| Keywords: | review; positron emission tomography; clinical practice; quality control; image analysis; cancer therapy; radiation exposure; neuroendocrine tumor; prostate cancer; dosimetry; lymphoma; radiopharmaceutical agent; imaging; nuclear medicine; thyroid cancer; radioisotope; radiation protection; theranostics; single photon emission computed tomography; radioactive waste; procedures; thyrotoxicosis; good manufacturing practice; human |
| Journal Title: | Lancet Oncology |
| Volume: | 25 |
| Issue: | 6 |
| ISSN: | 1470-2045 |
| Publisher: | Elsevier Science, Inc. |
| Date Published: | 2024-06-01 |
| Start Page: | e260 |
| End Page: | e269 |
| Language: | English |
| DOI: | 10.1016/s1470-2045(24)00041-x |
| PROVIDER: | scopus |
| PUBMED: | 38821100 |
| DOI/URL: | |
| Notes: | Review -- Source: Scopus |
